Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine ameliorates lipopolysaccharide-induced airway inflammation and bronchial hyperreactivity in mice
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Yasemin Karaman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye-Ankara, Turkey. Hauptthemen laut MEDLINE: Arginine, Bronchial Hyperreactivity, Nitric Oxide Synthase, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Hacettepe University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Objectives
Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor. ADMA concentrations are augmented in lung, plasma samples of asthmatics. It remains unclear whether the increased concentration of ADMA in airway inflammation contributes to the pathophysiology or acts as a protective mechanism. The objective of this study was to evaluate the effects of exogenous ADMA on airway inflammation in mice.
Methods
Ex vivo/in vivo airway inflammation models were used. Tracheal tissues, isolated from female Balb/c mice were incubated with lipopolysaccharide (LPS), ADMA, or LPS + ADMA for 4 days in tissue culture. Tracheal reactivity was evaluated afterward by agonist-induced contraction responses. Female Balb/c mice were applied i.n. LPS (0,1 mg/ml) to induce in vivo airway inflammation. ADMA (30 mg/kg) was administered by i.n. route 1 h before and 24 h after LPS application. Key findings I.n. ADMA application augmented lung ADMA levels, reduced nitrite levels in bronchoalveolar lavage (BAL) fluid, prevented bronchial hyperreactivity and airway inflammation. ADMA also prevented bronchial hyperreactivity when applied 15 min before methacholine nebulization during the assessment of airway function.
Conclusion
Exogenously applied ADMA may have protective effects in airway inflammation by limiting excessive nitric oxide (NO) production. Targeting the DDAH/ADMA/NOS pathway may provide a therapeutic approach for airway inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye-Ankara, Turkey.
- Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Üniversite Mah. 61080 Ortahisar-Trabzon, Turkey.
- Department of Pathology, Faculty of Medicine, Hacettepe University, 06100 Sıhhiye-Ankara, Turkey.
ORCID-Profile: Yasemin Karaman
Förderung
- Hacettepe University Scientific Research Projects Coordination Unit
Zitieren
APA
Karaman, Y., Kaya-Yasar, Y., Onder, S. C., Bozkurt, T. E., & Sahin-Erdemli, I. (2026). Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine ameliorates lipopolysaccharide-induced airway inflammation and bronchial hyperreactivity in mice. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf112
Vancouver
Karaman Y, Kaya-Yasar Y, Onder SC, Bozkurt TE, Sahin-Erdemli I. Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine ameliorates lipopolysaccharide-induced airway inflammation and bronchial hyperreactivity in mice. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf112
BibTeX
@article{Karaman2026,
author = {Karaman, Yasemin and Kaya-Yasar, Yesim and Onder, Sevgen Celik and Bozkurt, Turgut Emrah and Sahin-Erdemli, Inci},
title = {Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine ameliorates lipopolysaccharide-induced airway inflammation and bronchial hyperreactivity in mice},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf112}
}
EUVIMED